Advances in Tumor-Infiltrating Lymphocyte (TIL) as a Prognostic Factor and for Treating Invasive Cutaneous Melanoma

Invasive cutaneous melanoma is responsible for about 5% of skin tumors yet is liable for nearly 70% of skin cancer-related deaths. Despite notable advancements over the past decade, including immunotherapies and targeted treatments, more than half of invasive melanoma patients ultimately succumb to...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 25; no. 23; p. 12596
Main Authors:	de Oliveira, Gabriel Alves Freiria, de Oliveira, Daniel Arcuschin, Nisimoto, Melissa Yoshimi Sakamoto Maeda, Rubinho, Rafael, Gomes, Heitor Carvalho, Marti, Luciana Cavalheiro, de Oliveira Filho, Renato Santos
Format:	Journal Article
Language:	English
Published:	23-11-2024
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Invasive cutaneous melanoma is responsible for about 5% of skin tumors yet is liable for nearly 70% of skin cancer-related deaths. Despite notable advancements over the past decade, including immunotherapies and targeted treatments, more than half of invasive melanoma patients ultimately succumb to the disease due to therapeutic resistance. To overcome this obstacle, strategies such as combining immunotherapies with targeted drugs or adding epigenetic therapies have been investigated. Tumor-infiltrating lymphocytes (TILs) therapy has emerged as a promising option for patients whose disease continues to progress despite standard treatments. This article aims to introduce TIL therapy and review recent outcomes in melanoma prognosis in its application for melanoma management.
ISSN:	1422-0067 1422-0067
DOI:	10.3390/ijms252312596